RFA-CA-21-033: The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 9, 2021.
From the official notice on Grants.gov, last changed June 1, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$991,636
- Typical project length8.5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-21-033 were run by National Cancer Institute (NCI, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-033 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-CA-22-054 | August 19, 2022 | Closed September 19, 2022 | Closed |
| RFA-CA-22-039 | July 18, 2022 | Closed September 19, 2022 | Closed |
Key dates
| Posted | June 1, 2021 |
|---|---|
| Deadline | September 9, 2021 |
| Archived by Grants.gov | October 15, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (61% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.
Funded under RFA-CA-21-033 so far
NIH funded 8 projects under RFA-CA-21-033 in fiscal 2022 to 2026, at 7 institutions. The median yearly award was $991,636.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Fred Hutchinson Breast Cancer Clinical Validation Center | Fred Hutchinson Cancer Center | 2026 | $1.1 million |
| Clinical Validation Center for Early Detection of Pancreatic Cancer | New York University School of Medicine | 2026 | $845,682 |
| Blood-Based Testing for Advanced Adenoma | University of Pittsburgh at Pittsburgh | 2026 | $953,404 |
| Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation | Case Western Reserve University | 2026 | $1.0 million |
| Clinical Validation Center for Hepatocellular Carcinoma | UT Southwestern Medical Center | 2026 | $1.0 million |
| Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer | Vanderbilt University Medical Center | 2025 | $1.9 million |
| Great Lakes New England Clinical Validation Center | University of TX MD Anderson Can Ctr | 2025 | $2.0 million |
| Clinical Validation Center for Lung Cancer Early Detection | University of TX MD Anderson Can Ctr | 2025 | $2.1 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-21-033 still open?
No. It closed on September 9, 2021.
Who can apply for The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)?
Closed September 9, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-CA-21-033?
NIH RePORTER lists 8 projects funded under RFA-CA-21-033 in fiscal 2022 to 2026, at 7 institutions. The most were at University of TX MD Anderson Can Ctr, Fred Hutchinson Cancer Center, New York University School of Medicine.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)